Home
overview
Angiogenesis, the growth of new blood vessels, plays an important role in different diseases. Angiogenic inhibitors can aid treatments of cancer and stimulants aid occluded vascular diseases. Researchers have answered many questions but many still remain unanswered. A number a clinical trials are underway to establish side effects of angiogenesis, the treatment times and whether tumour cells will find other routes to vascularisation. This conference will keep all those involved in angiogenesis therapeutics up to date with the current advances in drug discovery, pre-clinical developments, early phase trials and drug delivery technologies. It will appeal to senior managers and directors from pharmaceutical and biotechnology companies, drug delivery companies and clinical research organisations.

A unique opportunity to learn from leading industry experts including:
Dr W Gregory Roberts, Senior Research Investigator, Pfizer
Dr Steve Wedge, Associate Director, AstraZeneca
Dr Mitchell Finer, Vice President, Research & Development, Gencell
Dr Gregory Robinson, Discovery, Ophthalmology, Pharmacia
Dr Francesc Mitjans, Project Leader, Merck Farma y Quimica
Dr King Li, Associate Director, Radiology & Imaging Sciences, National Institutes of Health
Dr Gerber Hans-Peter, Scientist, Genentech
Dr Stuart Naylor, Vice President, Biological Systems, Oxford BioMedica

Benefits of attending:
Angiogenesis imaging: discover the opportunities and challenges
Inhibition of VEGF receptors: understand the biology and clinical implications
Tumour angiogenesis: find out the latest developments and future expectations
Anti-angiogenic agents: evaluate drug mechanisms
Cancer discover new opportunities for improving research
Angiogenic gene therapies: learn about the new developments

“I recommend to you SMi’s forthcoming conference ‘Angiogenesis’. This conference will cover the advances in this area, which range from well-known applications in the cancer field to the more recent developments in retinopathy and cardiovascular disease. These are interesting times for these two classes of molecules as their true potential is starting to be realised in the clinic”.
Dr Neill MacKenzie, Senior Vice President, Business Development, Oxford BioMedica

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Neill MacKenzie

Dr Neill MacKenzie, Chief Business Officer, Avidex

9:10 DRUG DEVELOPMENT OF AGENTS INHIBITING ABERRANT NEOVASCULATURE

Dr David Sherris

Dr David Sherris, Chief Executive Officer, Sherris Pharma Partners

  • Overview of neovascularisation: vasculogenesis, arteriogenesis, angiogenesis, co-option, vascular mimicry
  • Class distinction of agents inhibiting neovascularisation
  • Use of angiogenesis assays in preclinical development
  • Development of anti-angiogenic drugs: the clinical dilemma
  • 9:40 ANGIOGENESIS IMAGING

    Dr King Li

    Dr King Li, Associate Director, Radiology & Imaging Sciences, National Institutes of Health

  • Review current usage of imaging in clinical trials of anti-angiogenic agents
  • Review information content and limitations of different clinical imaging tests
  • Review potential utility of imaging in pre-clinical drug development
  • Review potential new ways of integrating imaging in clinical trials of combination therapy
  • Present new data on molecular imaging
  • Present new data on image guided tissue analysis
  • 10:20 TUMOUR ANGIOGENESIS

    Dr Francesc Mitjans

    Dr Francesc Mitjans, Project Leader, Merck Farma y Quimica

  • Cell adhesion molecules
  • Alpha-v integrins and tumour angiogenesis
  • Research developments
  • In vivo tumour models
  • Results from pre-clinical studies
  • Future developments
  • 11:00 Morning Coffee

    11:20 A MODEL OF TUMOUR ANGIOGENESIS USING LASER CAPTURE MICRODISSECTION OF ENDOTHELIAL CELLS AND CDNA MICROARRAYS

    Dr Catherine Tribouley

    Dr Catherine Tribouley, Senior Scientist, Incyte Genomics

  • Selection of specimens and laser capture microdissection strategy
  • Clinical data and patient history collection
  • RNA amplification technology and cDNA microarray platform selection validation study
  • Principles of bioinformatics analysis and clustering of data
  • Functional analysis of genes identified
  • 12:00 ANTI-ANGIOGENESIS AND ANTI-TUMOUR ACTIVITIES OF ANTIBODIES AGAINST VEGFR1

    Dr Peter Bohlen

    Dr Peter Bohlen, Senior Vice President, Research, ImClone Systems

  • Neutralising VEGFR1 antibody inhibits angiogenesis by interfering with endothelial progenitor cell mobilisation from bone marrow
  • Endothelial cells and many tumour cells express VEGFR1. Many mammary carcinoma samples from patients are VEGFR1-positive
  • VEGFR1 expression on mammary cancer cells drives cancer growth
  • Neutralising VEGFR1 antibody inhibits breast cancer growth in mouse xenograft models by angiogenesis-dependent and independent mechanisms
  • Neutralising VEGFR1 antibody also inhibits inflammatory conditions by interfering with hematopoietic stem cell recruitment from bone marrow. This mechanism may further contribute to anti-tumour activity
  • Targeting VEGFR1 in VEGFR1-positive breast cancers and possibly other tumours may afford unique therapeutic opportunity to inhibit multiple disease mechanisms with one drug
  • 12:40 Lunch

    13:40 INHIBITION OF VEGF RECEPTOR TYROSINE KINASE ACTIVITY IN CANCER

    Dr Steve Wedge

    Dr Steve Wedge, Associate Director, AstraZeneca

  • ZD6474 is a potent, orally active, low molecular weight inhibitor of VEGF receptor tyrosine kinase activity
  • The compound has been shown to inhibit VEGF signalling and angiogenesis in vivo and demonstrates broad-spectrum activity in pre-clinical tumour models
  • ZD6474 is currently in clinical development as a once-daily oral therapy in patients with advanced cancer
  • 14:20 PHARMACOLOGICAL CHARACTERISATION OF CP-547, 632

    Dr W Gregory Roberts

    Dr W Gregory Roberts, Senior Research Investigator, Pfizer

  • In vitro characterisation
  • In vivo pharmacology
  • 15:00 ANGIOGENESIS AND GENETIC INSTABILITY OF CANCER

    Dr Valery Alakhov

    Dr Valery Alakhov, Vice President, Research & Development & Chief Scientific Officer, Supratek Pharmaceuticals

  • Induction of genetic instability in cancer cells and cancer progression
  • Genetic instability as a driving force of cancer induced activation of endothelium
  • Progressing tumour tissue as pro-angiogenic factor
  • New potential targets in the tumour – endothelium interactions
  • Therapeutic approaches to intervene with these targets
  • 15:40 Afternoon Tea

    16:00 VASCULAR TARGETING AGENTS

    Dr David Chaplin

    Dr David Chaplin, Chief Scientific Officer & Head, Research & Development, Oxigene

  • Comparing vascular targeting with anti-angiogenic approaches
  • Tubulin depolymerising agents as neovascular damaging agents
  • Combretastatin A4 phosphate: preclinical and clinical experience
  • Future directions for VTA development
  • 16:40 ANGIOGENESIS INHIBITORS (AI) IN CANCER: AN INFANT CLASS WITH PITFALLS AND POTENTIAL

    Ms Fil Manuguid

    Ms Fil Manuguid, Oncology Business Director, Datamonitor

  • Advantages in cancer treatment
  • Disadvantages in cancer treatment
  • SWOT analysis – market analysis of the strengths, weaknesses, opportunities and threats to key AIs
  • Competitive analysis of early and late stage products
  • Current patient potential for cancer AIs
  • Strategic outlook – sales forecasts for cancer AIs

    Challenges and obstacles to cancer AI usage

  • 17:20 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Prof Claire Lewis

    Prof Claire Lewis, Research Director, BioActa

    9:10 TARGETING VEGF LIGANDS OR RECEPTORS

    Dr Gerber Hans-Peter

    Dr Gerber Hans-Peter, Scientist, Genentech

  • VEGF’s autocrine and paracrine effector functions during angiogenesis and hematopoiesis
  • The autocrine loop by VEGF in hematopoietic malignancies
  • Therapeutic strategies targeting VEGF and VEGF induced signal transduction and their potential to interfere with autocrine and paracrine effector functions
  • 9:40 INHIBITORS OF ABERRANT ANGIOGENESIS

    Dr Gregory Robinson

    Dr Gregory Robinson, Discovery, Ophthalmology, Pharmacia

  • VEGF/VEGF R2 expression
  • Ocular setting
  • Novel uses
  • 10:20 EXPLORING THE THERAPEUTIC VALUE OF POTENTIAL ANTI-ANGIOGENIC AGENTS

    Dr Jocelyn Holash

    Dr Jocelyn Holash, Associate Director, Tumour Angiogenesis, Regeneron Pharmaceuticals

  • VEGF promotes vascular leak and angiogenesis in a number of disease settings
  • The VEGF-Trap, a novel and potent blocker of VEGF, may be efficacious in treating these diseases
  • Besides its therapeutic potential, the VEGF-Trap is an invaluable research tool that is allowing us to evaluate potential angiogenic factors and dissect the pathways of blood vessel growth
  • By evaluating the angiogenic potential of agents in the absence of VEGF, we are able to gain a truer understanding of their roles in angiogenesis
  • 11:00 Morning Coffee

    11:20 ANGIOGENESIS DRUG DISCOVERY

    Dr Chaoyong Ma

    Dr Chaoyong Ma, Business Development Manager, Phylonix Pharmaceuticals

  • HTS in vivo drug screening using a micro-plate format
  • Visual whole animal screens for assessing multiple effects
  • Rapid assessment of gene knockdown for target validation
  • 12:00 GENE THERAPY OF CARDIOVASCULAR DISEASE WITH ANGIOGENIC GROWTH FACTORS

    Dr Mitchell Finer

    Dr Mitchell Finer, Vice President, Research & Development, Gencell

  • pCOR: a safety optimised plasmid DNA delivery vectors for gene therapy
  • Preclinical proof of concept in the hind-limb ischemia model
  • Design and objectives of the phase 1 study in PAOD patients
  • Outcome in patients six months post treatment
  • Conclusions and next steps
  • 12:40 Lunch

    14:00 EXPLOITING THE HYPOXIA RESPONSE FOR THE DEVELOPMENT OF PRO OR ANTI-ANGIOGENIC THERAPIES

    Dr Stuart Naylor

    Dr Stuart Naylor, Vice President, Biological Systems, Oxford BioMedica

  • Hypoxia: role in disease progression, targeting for driving therapeutic application and therapeutic discovery
  • Exploiting hypoxia for targeted gene therapy
  • Exploiting the hypoxia signalling pathway for ‘targeted’ gene discovery
  • Targeting the hypoxia signalling pathway for the development of novel pro-angiogenic therapeutics
  • 14:40 MINING HUMAN FIBRINOGEN AS A SOURCE OF NEW ANTI-ANGIOGENIC AGENTS

  • Normal haemostatic functions of fibrinogen – role in blood clotting and enzymatic cleavage into fragments
  • Anti-angiogenic effects of the central E fragment of human fibrinogen in vitro and in vivo
  • Anti-angiogenic effects of a novel 24-amino acid peptide derived from the amino terminus of the alpha chain of human fibrinogen (termed ‘Alphastatin’) in vitro
  • Anti-vascular properties of Alphastatin in vivo
  • Prof Claire Lewis

    Prof Claire Lewis, Research Director, BioActa

    Dr Nicola Brown

    Dr Nicola Brown, Co-Research Director, BioActa

    15:20 Afternoon Tea

    15:40 NOVEL ANTI-ANGIOGENIC COMPOUND BASED ON THE STRUCTURE AND ACTIVITY OF THALIDOMIDE

    Dr David Stirling

    Dr David Stirling, Chief Scientific Officer, Executive Vice President, Pharmaceutical Research & Development, Celgene

  • Thalidomide is a clinically active anti-angiogenic agent
  • Thalidomide analogues with improved anti-angiogenic activity
  • PDE 4 inhibition and angiogenesis
  • Improved angiogenesis assays
  • Clinical development of new anti-angiogenic agents
  • 16:20 DEVELOPMENT OF ANGIOGENESIS-INHIBITORY DRUGS AT ENTREMED

    Dr John Holaday

    Dr John Holaday, Chairman & Chief Executive Officer, EntreMed

  • Clinical update on Angiostatin, Endostatin and Panzem
  • Preclinical and clinical development of thalidomide analogues
  • 2ME2 analogue program
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    Determining and Validating Biomarkers for Angiogenesis Trials
    Workshop

    Determining and Validating Biomarkers for Angiogenesis Trials

    The Hatton, at etc. venues
    19th February 2003
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.